CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

N/A

Manufactured by Bausch Health US, LLC

579 FDA adverse event reports analyzed

Last updated: 2026-04-15

About CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Bausch Health US, LLC. The most commonly reported adverse reactions for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE include DRUG INEFFECTIVE, ERYTHEMA, ACNE, PRURITUS, RASH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE.

Top Adverse Reactions

DRUG INEFFECTIVE33 reports
ERYTHEMA26 reports
ACNE25 reports
PRURITUS25 reports
RASH20 reports
DRY SKIN16 reports
EXPIRED PRODUCT ADMINISTERED15 reports
SKIN DISCOLOURATION13 reports
NAUSEA12 reports
BURNING SENSATION11 reports
OFF LABEL USE11 reports
SWELLING FACE11 reports
APPLICATION SITE ERYTHEMA10 reports
APPLICATION SITE PAIN10 reports
DIZZINESS10 reports
PRODUCT QUALITY ISSUE10 reports
CONDITION AGGRAVATED9 reports
DIARRHOEA9 reports
EYE SWELLING9 reports
HYPERSENSITIVITY9 reports
NO ADVERSE EVENT9 reports
PAIN9 reports
DEPRESSION8 reports
SKIN BURNING SENSATION8 reports
SUICIDAL IDEATION8 reports
BLOOD PRESSURE INCREASED7 reports
SKIN EXFOLIATION7 reports
ANXIETY6 reports
SKIN IRRITATION6 reports
URTICARIA6 reports
ABDOMINAL PAIN5 reports
APPLICATION SITE PRURITUS5 reports
HEADACHE5 reports
MIGRAINE5 reports
PARAESTHESIA5 reports
SWELLING5 reports
WEIGHT DECREASED5 reports
ABDOMINAL DISTENSION4 reports
ACCIDENTAL EXPOSURE TO PRODUCT4 reports
ALOPECIA4 reports
BRONCHITIS4 reports
COLITIS4 reports
DEHYDRATION4 reports
EXPOSURE DURING PREGNANCY4 reports
FATIGUE4 reports
FEELING ABNORMAL4 reports
INJECTION SITE PAIN4 reports
MALAISE4 reports
PAIN IN EXTREMITY4 reports
PERIPHERAL SWELLING4 reports
PRODUCT USE ISSUE4 reports
RASH ERYTHEMATOUS4 reports
SOMNOLENCE4 reports
STRESS4 reports
ALLERGY TO ARTHROPOD STING3 reports
APPLICATION SITE IRRITATION3 reports
APPLICATION SITE SWELLING3 reports
ARTHRALGIA3 reports
BACK PAIN3 reports
DERMATITIS ATOPIC3 reports
DRUG HYPERSENSITIVITY3 reports
ECZEMA3 reports
IRRITABILITY3 reports
MUSCLE SPASMS3 reports
NEPHROLITHIASIS3 reports
PRODUCT USE IN UNAPPROVED INDICATION3 reports
RESTLESS LEGS SYNDROME3 reports
TREATMENT NONCOMPLIANCE3 reports
URINARY TRACT INFECTION3 reports
VISION BLURRED3 reports
ABDOMINAL PAIN UPPER2 reports
ACNE CYSTIC2 reports
APPLICATION SITE DRYNESS2 reports
APPLICATION SITE EXFOLIATION2 reports
APPLICATION SITE RASH2 reports
BACK INJURY2 reports
BLISTER2 reports
BOWEL MOVEMENT IRREGULARITY2 reports
CONTRAINDICATED PRODUCT ADMINISTERED2 reports
COUGH2 reports
DEATH2 reports
DECREASED APPETITE2 reports
DERMATITIS CONTACT2 reports
DISCOMFORT2 reports
DISTURBANCE IN ATTENTION2 reports
DRUG ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE2 reports
DRUG DOSE OMISSION2 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION2 reports
DRUG INTERACTION2 reports
DRUG WITHDRAWAL SYNDROME2 reports
DYSPEPSIA2 reports
EXPOSURE DURING BREAST FEEDING2 reports
EXTRA DOSE ADMINISTERED2 reports
FALL2 reports
GALLBLADDER DISORDER2 reports
GASTROINTESTINAL DISORDER2 reports
HAEMATOCHEZIA2 reports
HYPOTENSION2 reports
HYPOXIA2 reports
ILLNESS2 reports

Report Outcomes

Out of 307 classified reports for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE:

Serious 26.4%Non-Serious 73.6%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female240 (80.5%)
Male58 (19.5%)

Reports by Age

Age 1510 reports
Age 168 reports
Age 208 reports
Age 228 reports
Age 268 reports
Age 177 reports
Age 247 reports
Age 256 reports
Age 296 reports
Age 145 reports
Age 215 reports
Age 305 reports
Age 124 reports
Age 184 reports
Age 234 reports
Age 324 reports
Age 354 reports
Age 394 reports
Age 404 reports
Age 414 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE?

This profile reflects 579 FDA FAERS reports that mention CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, ERYTHEMA, ACNE, PRURITUS, RASH, DRY SKIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE?

Labeling and FAERS entries often list Bausch Health US, LLC in connection with CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.